Hepatic Disease in Patients With HIV
Summary
- Lamivudine is appropriate for use in persons coinfected with HIV and HBV if administered in combination with other agents with anti-HBV activity in the context of an antiretroviral therapy regimen and at the dose used in the treatment of HIV (300 mg daily) (Management Guidelines)[DHHS ART]
- Incidence of lamivudine-resistant HBV is approximately 20% per year in people with HIV if taken as monotherapy for HBV and reaches 90% at 4 years[Dore 1999; Benhamou 1999; Pillay 2000]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content